Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.60 |
| ▸ | HPGDS | O60760 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265434 | 1.00 | MEN1 (0.60) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2262991 | 0.95 | KDM1A (0.60) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2262996 | 0.95 | KDM1A (0.60) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2266235 | 0.94 | MEN1 (0.55) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2266242 | 0.94 | MEN1 (0.55) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2259629 | 0.93 | KDM1A (0.55) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2262001 | 0.93 | KDM1A (0.57) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2262005 | 0.93 | KDM1A (0.57) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2259637 | 0.93 | KDM1A (0.55) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2259793 | 0.92 | MEN1 (0.60) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349982-B1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA S R L (IT) | 2015-08-05 | — | — | EP | disclosed |
| US-8669261-B2 | Acrylomido derivatives useful as inhibitors of the mitochondrial permeability transition | Congenia SLR (IT) | 2014-03-11 | — | — | US | disclosed |
| US-20130245019-A1 | ACRYLOMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA SRL (IT) | 2013-09-19 | — | — | US | disclosed |
| US-8470831-B2 | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition | Cogenia SRL (IT) | 2013-06-25 | — | — | US | disclosed |
| US-20110195977-A1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA SRL (IT) | 2011-08-11 | — | — | US | disclosed |
| EP-2349982-A1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | Congenia S.r.l. (IT) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010049768-A1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA SRL (IT) | 2010-05-06 | — | — | WO | disclosed |
| EP-2179984-A1 | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition | Congenia S.r.l. (IT) | 2010-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195977-A1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | AIFM1, TFAM, NDUFAB1 | MEN1 4861/4885KMT2A 4824/4885RAB9A 783/4885 |
| US-20130245019-A1 | ACRYLOMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | AIFM1, TFAM, NDUFAB1 | MEN1 4863/4885KMT2A 4857/4885RAB9A 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.